LICENSE AGREEMENT between 4D Molecular Therapeutics, Inc. and ASTELLAS GENE THERAPIES, INC. Dated as of July 5, 2023License Agreement • November 9th, 2023 • 4D Molecular Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This License Agreement (the “Agreement”) is made and entered into effective as of July 5, 2023 (the “Effective Date”) by and between 4D Molecular Therapeutics, Inc., a Delaware corporation (“Licensor”), and Astellas Gene Therapies, Inc. (f/k/a Audentes Therapeutics, Inc.), a Delaware corporation (“AGT”). Licensor and AGT are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
